| Code | CSB-RA011877MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Abituzumab, targeting integrin alpha-V (ITGAV). ITGAV forms heterodimeric complexes with various beta subunits, creating receptors that mediate cell adhesion to extracellular matrix proteins through recognition of RGD motifs. These integrin complexes play critical roles in cell migration, proliferation, and survival, while also regulating angiogenesis and tissue remodeling. Aberrant ITGAV expression and signaling have been implicated in cancer progression, metastasis, and fibrotic diseases, making it an important therapeutic target in oncology and related pathological conditions.
Abituzumab, the reference antibody, is a humanized IgG2 monoclonal antibody that specifically binds to integrin αVβ1, αVβ3, αVβ5, and αVβ6 complexes. Originally developed for cancer therapy, it has been investigated in clinical trials for various solid tumors including colorectal and prostate cancers. This biosimilar provides researchers with a valuable tool for investigating integrin-mediated signaling pathways, tumor microenvironment interactions, and mechanisms of cancer cell invasion and metastasis in preclinical models.
There are currently no reviews for this product.